Oxurion's Anti-PIGF Antibody Disappoints in Diabetic Macular Edema
Executive Summary
The primary endpoint was missed in a Phase IIa study of Oxurion’s THR-317 in diabetic macular edema, but vision did improve in two patient subgroups.
You may also be interested in...
Vision Failure Means End Of The Road For Oxurion
Disappointing data from a trial of the last remaining drug in its pipeline means that the Belgium group formerly known as ThromboGenics is closing its doors after more than 30 years.
Oxurion Pins Hopes On THR-149 After THR-687 Flops In DME
THR-687’s failure in Phase II marks the second drug to flunk in the disease after a Phase IIa study of THR-317 showed disappointing results in 2019, but THR-149 has shown some encouraging data.
Oxurion Eyes $12bn Opportunity After Restructuring
The Belgium-headquartered group is pulling the plug on its dry AMD research efforts and investments in cancer venture Oncurious to focus on two early-stage compounds that show promise for diabetic macular edema and other retinal diseases.